National Cancer Institute (U.S.), 2026-11-20: NCI clinical-trials record for a Johns Hopkins pediatric brain-tumor study of oral mebendazole. It lists the trial objective as finding the maximum tolerated dose in recurrent or progressive pediatric brain tumors.
To determine the maximum tolerated dose (MTD) of oral mebendazole in patients with recurrent/progressive pediatric brain tumors
n/a
National Cancer Institute (U.S.), 2026-11-20: NCI clinical-trials record for a Johns Hopkins pediatric brain-tumor study of oral mebendazole. It lists the trial objective as finding the maximum tolerated dose in recurrent or progressive pediatric brain tumors. Record field quoted from the trial objectives; NCI trial record, not prose. Study type: phase 1 dose-finding trial. Country: United States. Sponsor: Johns Hopkins (NCT02644291). The NCI page reproduces the registry record; it does not post results. Access date 2026-11-20; page undated. This is a cancer-body statement that the trial exists, not evidence of efficacy. Same trial as NCT02644291 (MBC-03).
